<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p156" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_156{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_156{left:306px;bottom:30px;}
#t3_156{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_156{left:346px;bottom:30px;}
#t5_156{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_156{left:517px;bottom:30px;}
#t7_156{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_156{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_156{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_156{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_156{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:-0.67px;}
#tc_156{left:35px;bottom:754px;letter-spacing:0.12px;word-spacing:0.06px;}
#td_156{left:35px;bottom:731px;letter-spacing:0.1px;word-spacing:-0.27px;}
#te_156{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:0.08px;}
#tf_156{left:35px;bottom:684px;letter-spacing:0.06px;word-spacing:0.13px;}
#tg_156{left:306px;bottom:692px;letter-spacing:-0.01px;}
#th_156{left:35px;bottom:645px;letter-spacing:0.02px;word-spacing:0.17px;}
#ti_156{left:35px;bottom:622px;letter-spacing:0.14px;word-spacing:-0.56px;}
#tj_156{left:35px;bottom:599px;letter-spacing:0.09px;word-spacing:0.11px;}
#tk_156{left:376px;bottom:606px;letter-spacing:-0.01px;}
#tl_156{left:400px;bottom:599px;letter-spacing:0.03px;word-spacing:0.16px;}
#tm_156{left:35px;bottom:575px;letter-spacing:0.05px;word-spacing:0.14px;}
#tn_156{left:532px;bottom:583px;letter-spacing:-0.01px;}
#to_156{left:555px;bottom:575px;letter-spacing:-0.37px;}
#tp_156{left:35px;bottom:552px;letter-spacing:0.14px;word-spacing:0.04px;}
#tq_156{left:35px;bottom:529px;letter-spacing:0.21px;word-spacing:-0.44px;}
#tr_156{left:232px;bottom:529px;}
#ts_156{left:248px;bottom:529px;letter-spacing:0.24px;word-spacing:-0.05px;}
#tt_156{left:35px;bottom:506px;letter-spacing:0.05px;word-spacing:0.14px;}
#tu_156{left:342px;bottom:513px;letter-spacing:-0.01px;}
#tv_156{left:365px;bottom:506px;letter-spacing:0.08px;word-spacing:0.15px;}
#tw_156{left:35px;bottom:482px;letter-spacing:0.13px;word-spacing:-0.87px;}
#tx_156{left:373px;bottom:490px;letter-spacing:-0.01px;}
#ty_156{left:396px;bottom:482px;letter-spacing:0.1px;word-spacing:0.09px;}
#tz_156{left:35px;bottom:459px;letter-spacing:0.03px;word-spacing:0.16px;}
#t10_156{left:35px;bottom:436px;letter-spacing:0.16px;word-spacing:0.03px;}
#t11_156{left:35px;bottom:413px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t12_156{left:233px;bottom:413px;}
#t13_156{left:249px;bottom:413px;letter-spacing:0.02px;word-spacing:0.16px;}
#t14_156{left:35px;bottom:390px;letter-spacing:-0.12px;}
#t15_156{left:100px;bottom:397px;letter-spacing:-0.01px;}
#t16_156{left:35px;bottom:349px;letter-spacing:0.15px;word-spacing:0.04px;}
#t17_156{left:35px;bottom:326px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t18_156{left:35px;bottom:303px;letter-spacing:0.06px;word-spacing:0.12px;}
#t19_156{left:35px;bottom:280px;letter-spacing:0.09px;word-spacing:-0.05px;}
#t1a_156{left:528px;bottom:287px;letter-spacing:0.12px;}
#t1b_156{left:35px;bottom:256px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t1c_156{left:35px;bottom:233px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1d_156{left:35px;bottom:195px;letter-spacing:-0.09px;word-spacing:0.51px;}
#t1e_156{left:35px;bottom:171px;letter-spacing:0.05px;word-spacing:-0.92px;}
#t1f_156{left:35px;bottom:148px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1g_156{left:35px;bottom:124px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1h_156{left:35px;bottom:101px;letter-spacing:0.13px;word-spacing:-0.74px;}
#t1i_156{left:35px;bottom:78px;letter-spacing:0.13px;word-spacing:0.07px;}
#t1j_156{left:545px;bottom:85px;}
#t1k_156{left:551px;bottom:78px;letter-spacing:0.45px;}
#t1l_156{left:562px;bottom:85px;}
#t1m_156{left:35px;bottom:55px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t1n_156{left:618px;bottom:777px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1o_156{left:618px;bottom:754px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1p_156{left:618px;bottom:731px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t1q_156{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1r_156{left:618px;bottom:684px;letter-spacing:0.1px;word-spacing:-0.07px;}
#t1s_156{left:1133px;bottom:692px;}
#t1t_156{left:618px;bottom:661px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1u_156{left:618px;bottom:638px;letter-spacing:0.11px;word-spacing:-0.69px;}
#t1v_156{left:618px;bottom:614px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1w_156{left:1001px;bottom:622px;letter-spacing:0.1px;}
#t1x_156{left:1046px;bottom:614px;letter-spacing:-0.08px;word-spacing:0.27px;}
#t1y_156{left:618px;bottom:591px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1z_156{left:618px;bottom:568px;letter-spacing:0.14px;word-spacing:0.05px;}
#t20_156{left:618px;bottom:545px;letter-spacing:0.18px;}
#t21_156{left:618px;bottom:522px;letter-spacing:-0.28px;}
#t22_156{left:660px;bottom:529px;letter-spacing:0.13px;}
#t23_156{left:721px;bottom:522px;letter-spacing:0.04px;word-spacing:0.14px;}
#t24_156{left:618px;bottom:498px;letter-spacing:0.19px;}
#t25_156{left:618px;bottom:475px;letter-spacing:0.08px;}
#t26_156{left:618px;bottom:436px;letter-spacing:0.03px;word-spacing:-0.36px;}
#t27_156{left:618px;bottom:413px;letter-spacing:0.05px;word-spacing:0.14px;}
#t28_156{left:618px;bottom:390px;letter-spacing:0.02px;word-spacing:0.16px;}
#t29_156{left:863px;bottom:397px;}
#t2a_156{left:908px;bottom:390px;word-spacing:0.2px;}
#t2b_156{left:618px;bottom:366px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2c_156{left:1003px;bottom:374px;letter-spacing:-0.01px;}
#t2d_156{left:1027px;bottom:366px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2e_156{left:618px;bottom:343px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2f_156{left:618px;bottom:320px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2g_156{left:618px;bottom:297px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2h_156{left:618px;bottom:273px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2i_156{left:618px;bottom:235px;letter-spacing:-0.07px;word-spacing:0.49px;}
#t2j_156{left:618px;bottom:198px;letter-spacing:0.19px;}
#t2k_156{left:618px;bottom:173px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2l_156{left:618px;bottom:150px;letter-spacing:0.09px;word-spacing:0.11px;}
#t2m_156{left:618px;bottom:127px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2n_156{left:618px;bottom:104px;letter-spacing:0.08px;}
#t2o_156{left:676px;bottom:111px;letter-spacing:0.1px;}
#t2p_156{left:720px;bottom:104px;letter-spacing:0.12px;word-spacing:-1.03px;}
#t2q_156{left:618px;bottom:80px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2r_156{left:948px;bottom:88px;}
#t2s_156{left:994px;bottom:80px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2t_156{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_156{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_156{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_156{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_156{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_156{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_156{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_156{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_156{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_156{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts156" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg156Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg156" style="-webkit-user-select: none;"><object width="1210" height="935" data="156/156.svg" type="image/svg+xml" id="pdf156" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_156" class="t s0_156">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_156" class="t s1_156">© </span>
<span id="t3_156" class="t s0_156">(NCCN </span>
<span id="t4_156" class="t s1_156">© </span>
<span id="t5_156" class="t s0_156">), All rights reserved. NCCN Guidelines </span>
<span id="t6_156" class="t s1_156">® </span>
<span id="t7_156" class="t s0_156">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_156" class="t s2_156">NCCN Guidelines Version 4.2024 </span>
<span id="t9_156" class="t s2_156">Head and Neck Cancers </span>
<span id="ta_156" class="t s3_156">MS-15 </span>
<span id="tb_156" class="t s4_156">significant difference was shown in the frequency of grade 3 or worse late </span>
<span id="tc_156" class="t s4_156">effects at 6 to 24 months after treatment start, among the various </span>
<span id="td_156" class="t s4_156">treatment groups. Long-term follow-up confirmed a statistically significant </span>
<span id="te_156" class="t s4_156">improvement in locoregional control and OS with hyperfractionation </span>
<span id="tf_156" class="t s4_156">compared to standard fractionation. </span>
<span id="tg_156" class="t s5_156">149 </span>
<span id="th_156" class="t s4_156">The MARCH meta-analysis, including individual patient data from 15 </span>
<span id="ti_156" class="t s4_156">randomized trials, analyzed the effect of hyperfractionated or accelerated </span>
<span id="tj_156" class="t s4_156">RT on survival of patients with H&amp;N cancers. </span>
<span id="tk_156" class="t s5_156">170 </span>
<span id="tl_156" class="t s4_156">Standard fractionation </span>
<span id="tm_156" class="t s4_156">constituted the control arm in all of the trials in this meta-analysis. </span>
<span id="tn_156" class="t s5_156">150 </span>
<span id="to_156" class="t s4_156">An </span>
<span id="tp_156" class="t s4_156">absolute survival benefit for altered fractionation of 3.4% at 5 years (HR, </span>
<span id="tq_156" class="t s4_156">0.92; 95% CI, 0.86–0.97; </span><span id="tr_156" class="t s6_156">P </span><span id="ts_156" class="t s4_156">= .003) was reported. This benefit, however, </span>
<span id="tt_156" class="t s4_156">was limited to patients &lt;60 years of age. </span>
<span id="tu_156" class="t s5_156">170 </span>
<span id="tv_156" class="t s4_156">Hyperfractionation was </span>
<span id="tw_156" class="t s4_156">associated with a benefit of 8% after 5 years. </span>
<span id="tx_156" class="t s5_156">171 </span>
<span id="ty_156" class="t s4_156">An update to the MARCH </span>
<span id="tz_156" class="t s4_156">meta-analysis, including data from 33 trials, continued to show a survival </span>
<span id="t10_156" class="t s4_156">benefit of hyperfractionation, compared to standard fractionation (HR, </span>
<span id="t11_156" class="t s4_156">0.83; 95% CI, 0.74–0.92; </span><span id="t12_156" class="t s6_156">P </span><span id="t13_156" class="t s4_156">&lt; .001), in patients with locally advanced </span>
<span id="t14_156" class="t s4_156">SCCHN. </span>
<span id="t15_156" class="t s5_156">172 </span>
<span id="t16_156" class="t s4_156">Consensus on the optimal use of altered fractionation schedules using </span>
<span id="t17_156" class="t s4_156">either concomitant boost or hyperfractionation for stage III or IV oral cavity, </span>
<span id="t18_156" class="t s4_156">oropharynx, supraglottic larynx, and hypopharyngeal squamous cell </span>
<span id="t19_156" class="t s4_156">cancers has not yet emerged among NCCN Member Institutions. </span>
<span id="t1a_156" class="t s5_156">170,173,174 </span>
<span id="t1b_156" class="t s4_156">Furthermore, as described below, using altered fractionation in conjunction </span>
<span id="t1c_156" class="t s4_156">with most concurrent systemic agents remains controversial. </span>
<span id="t1d_156" class="t s7_156">Fractionation in Concurrent Chemoradiation </span>
<span id="t1e_156" class="t s4_156">Panel members generally agree on conventionally fractionated radiation in </span>
<span id="t1f_156" class="t s4_156">combination with most concurrent systemic therapies in the definitive </span>
<span id="t1g_156" class="t s4_156">treatment setting. Most published studies have used conventional </span>
<span id="t1h_156" class="t s4_156">fractionation (at 2.0 Gy/fraction to a typical dose of 70 Gy in 7 weeks) with </span>
<span id="t1i_156" class="t s4_156">single-agent high-dose cisplatin (given every 3 weeks at 100 mg/m </span>
<span id="t1j_156" class="t s5_156">2 </span>
<span id="t1k_156" class="t s4_156">). </span>
<span id="t1l_156" class="t s5_156">32 </span>
<span id="t1m_156" class="t s4_156">Other fraction sizes (eg, 1.8 Gy/fraction), other dosing schedules of </span>
<span id="t1n_156" class="t s4_156">cisplatin (eg, weekly), other single concurrent agents, concurrent </span>
<span id="t1o_156" class="t s4_156">multiagent systemic therapy, and altered fractionation schedules with </span>
<span id="t1p_156" class="t s4_156">concurrent systemic therapy have been evaluated alone or in combination. </span>
<span id="t1q_156" class="t s4_156">Numerous trials have shown that altered fractionation and concurrent </span>
<span id="t1r_156" class="t s4_156">chemotherapy are more efficacious than altered fractionation alone. </span>
<span id="t1s_156" class="t s5_156">174-176 </span>
<span id="t1t_156" class="t s4_156">However, conversely, the GORTEC 99-02 trial reported that altered </span>
<span id="t1u_156" class="t s4_156">fractionation did not improve outcomes when compared with conventional </span>
<span id="t1v_156" class="t s4_156">fractionation given with concurrent chemotherapy. </span>
<span id="t1w_156" class="t s5_156">177,178 </span>
<span id="t1x_156" class="t s4_156">Similarly, RTOG </span>
<span id="t1y_156" class="t s4_156">0129 assessed accelerated fractionation with two cycles of concurrent </span>
<span id="t1z_156" class="t s4_156">cisplatin versus standard fractionation with three cycles of concurrent </span>
<span id="t20_156" class="t s4_156">cisplatin. There was no significant difference in OS between the two </span>
<span id="t21_156" class="t s4_156">arms, </span>
<span id="t22_156" class="t s5_156">32,179,180 </span>
<span id="t23_156" class="t s4_156">indicating that accelerated fractionation is not clearly more </span>
<span id="t24_156" class="t s4_156">efficacious than conventional fractionation in the setting of concurrent </span>
<span id="t25_156" class="t s4_156">chemotherapy. </span>
<span id="t26_156" class="t s4_156">Concurrent chemoradiation increases acute toxicity compared to radiation </span>
<span id="t27_156" class="t s4_156">alone, although an increase in late toxicity beyond that caused by RT </span>
<span id="t28_156" class="t s4_156">alone is less clearly established. </span>
<span id="t29_156" class="t s5_156">181-183 </span>
<span id="t2a_156" class="t s4_156">Multiagent systemic therapy may </span>
<span id="t2b_156" class="t s4_156">further increase the acute and late toxicity burden. </span>
<span id="t2c_156" class="t s5_156">184 </span>
<span id="t2d_156" class="t s4_156">For any </span>
<span id="t2e_156" class="t s4_156">chemotherapeutic approach, close attention should be paid to published </span>
<span id="t2f_156" class="t s4_156">reports for the specific chemotherapy agent, dose, and schedule of </span>
<span id="t2g_156" class="t s4_156">administration. Chemoradiation should be performed by an experienced </span>
<span id="t2h_156" class="t s4_156">team and should include state-of-the-art supportive care. </span>
<span id="t2i_156" class="t s7_156">Radiation Techniques </span>
<span id="t2j_156" class="t s6_156">IMRT </span>
<span id="t2k_156" class="t s4_156">Using contemporary computer-based planning and radiation delivery, the </span>
<span id="t2l_156" class="t s4_156">intensity of the radiation beam can be modulated to decrease doses to </span>
<span id="t2m_156" class="t s4_156">normal structures with minimal compromise of the doses to the cancer </span>
<span id="t2n_156" class="t s4_156">targets. </span>
<span id="t2o_156" class="t s5_156">185,186 </span>
<span id="t2p_156" class="t s4_156">Over the last 15 years, IMRT has displaced older techniques </span>
<span id="t2q_156" class="t s4_156">in the treatment of most H&amp;N malignancies. </span>
<span id="t2r_156" class="t s5_156">187-194 </span>
<span id="t2s_156" class="t s4_156">IMRT is a highly </span>
<span id="t2t_156" class="t s8_156">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
